For the well-known anticancer effect of ER-beta, this study suggested that LGD could represent the checkpoint for neoplastic evolution and ER-beta agonist function of supplemental formulation could promote apoptosis, thus slowing the progression towards carcinoma. Here, ESR2 is linked to carcinoma.